Highlights

  • Sigma Healthcare (ASX:SIG) reported FY26 revenue of AUD 10.8 billion, up 15.5% on its normalised pro-forma comparator.
  • FY26 normalised EBIT reached AUD 1.09 billion, up 20.6%, while normalised NPAT was AUD 732.3 million.
  • Australian Chemist Warehouse-branded sales increased 12.1% from 1 July to 16 October 2026, including 9.8% like-for-like growth.
  • International branded-store sales rose 30.2% in constant currency for the September quarter, with 15.8% like-for-like growth.

Sigma Healthcare Limited operates pharmacy retail brands and pharmaceutical distribution activities, combining Chemist Warehouse-branded stores with established wholesale operations. Its October 2026 annual general meeting update reported further domestic and international network sales growth after the group completed its first full financial year following the Chemist Warehouse merger. In trading on 29 October 2026, Sigma Healthcare (ASX:SIG) shares were quoted at AUD 2.755, up 1.29% at the time reflected by the market quotation. Operational attention remains on store additions, retail category demand, integration spending and delivery of planned synergies.

Company Business

Sigma Healthcare (ASX:SIG) operates across Australian pharmacy wholesale, retail franchising and international branded pharmacy networks. Its Chemist Warehouse, My Chemist, Amcal and Discount Drug Stores banners serve different customer segments, while wholesale distribution supplies prescription medicines and other pharmacy products. The group also supports branded pharmacies outside Australia, including operations in New Zealand and Ireland and arrangements in other international markets.

The operating model connects distribution infrastructure with pharmacy retail networks, creating exposure to pharmacy dispensing, non-prescription products and consumer health categories. The company distinguishes sales across Australian and international retail networks and reports comparisons including like-for-like store growth, which excludes the effect of changing store numbers. Expansion of the branded network and integration of the combined businesses remain central operating priorities.

Recent Development

At its 21 October 2026 annual general meeting, Sigma Healthcare (ASX:SIG) reported Australian Chemist Warehouse-branded store sales growth of 12.1% between 1 July and 16 October 2026. Like-for-like growth was 9.8%. For the international network, sales increased 30.2% in constant currency during the three months ended 30 September, while comparable-store sales grew 15.8%. The different measurement periods are important when comparing the domestic and overseas figures.

Sigma identified softer demand in selected discretionary categories, including women’s fragrances, vitamins and supplements, amid cost-of-living pressures. Beauty, healthcare and products supporting GLP-1 treatments showed different trading patterns. Management said the global pharmacy network was approaching 1,000 stores. For the first half of FY27, the company planned to onboard 14 Chemist Warehouse stores and 42 Amcal and Discount Drug Stores domestically, alongside 19 international stores.

The company also stated that it expected double-digit Chemist Warehouse-branded store sales growth for the remainder of the first half. This remains an outlook statement rather than an achieved result. The 21 October update predates the quoted 29 October market session, and the trading movement should not be attributed to that announcement.

Financial Performance and Sector Context

For the financial year ended 30 June 2026, Sigma Healthcare (ASX:SIG) reported revenue of AUD 10.8 billion, an increase of 15.5% compared with normalised pro-forma FY25. Normalised EBIT reached AUD 1,090.0 million, up 20.6%, and the corresponding margin was 10.1%. Normalised net profit after tax increased 22.3% to AUD 732.3 million. These growth rates use the company’s normalised pro-forma comparative base and should not be confused with statutory year-on-year comparisons following the merger.

Net debt stood at AUD 663 million at the FY26 year-end, with debt representing 0.57 times normalised EBITDA. Sigma reported AUD 32.6 million in integration synergies and retained a target of AUD 100 million in annual synergies by FY29. Australia generated 14.9% revenue growth and 18.3% normalised EBIT growth, while international normalised EBIT rose 91.3% to AUD 55.8 million. A fully franked final dividend of two Australian cents per share was declared, bringing the reported FY26 interim and final dividends to four cents per share.

Trading conditions vary across prescription products, health-related categories and discretionary retail merchandise. Household budgets can affect some front-of-store purchases, while regulation, pharmaceutical reimbursement arrangements and distribution costs are relevant to the industry. Sigma’s disclosures also show that expanding into new markets can change both revenue composition and operating requirements.

Risks to Consider

Sigma Healthcare (ASX:SIG) faces execution risks in combining systems, supply chains and retail operations after the merger. Synergy targets depend on implementation and the timing of integration expenditure. Cost-of-living pressures may continue to influence discretionary product sales. Pharmaceutical regulation, reimbursement arrangements, labour expenses, distribution reliability and competition can also affect margins. International expansion introduces foreign-exchange, property and market-specific operating considerations.

What to Watch Next

Key indicators include comparable sales growth during the Christmas trading period, first-half FY27 store onboarding and the balance between retail expansion and distribution capacity. Future results will clarify whether revenue growth translates into improved margins and cash generation. Subsequent disclosures will also show progress toward the AUD 100 million FY29 annual synergy target and the evolution of net debt following integration investment.

Key Insights

Sigma Healthcare (ASX:SIG) entered FY27 following a year of higher normalised earnings and a broader pharmacy network. October trading figures showed further increases in Chemist Warehouse-branded sales in Australia and overseas, alongside softer demand in selected discretionary categories. The next reporting periods will provide measures of comparable-store sales, network additions, integration progress and earnings conversion without requiring assumptions about future share-price performance.